Literature DB >> 6478456

Phase II trial of etoposide in advanced prostate cancer.

D L Trump, C L Loprinzi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6478456

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN： 0361-5960


× No keyword cloud information.
  5 in total

1.  Glutathione depletion increases the cytotoxicity of melphalan to PC-3, an androgen-insensitive prostate cancer cell line.

Authors:  A Canada; L Herman; K Kidd; C Robertson; D Trump
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

2.  Etoposide in prostatic cancer: experimental studies and phase II trial in patients with bidimensionally measurable disease.

Authors:  H I Scher; C Sternberg; W D Heston; R C Watson; D Niedzwiecki; T Smart; P Hollander; A Yagoda
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

3.  Etoposide, epirubicin and carboplatin in hormone-refractory prostate cancer.

Authors:  H Fuse; Y Muraishi; Y Fujishiro; T Katayama
Journal:  Int Urol Nephrol       Date:  1996       Impact factor: 2.370

4.  Chemotherapy for endocrine-therapy-refractory prostate cancer.

Authors:  S Akimoto; T Ohki; K Akakura; M Masai; J Shimazaki
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

Review 5.  Role of chemotherapy in prostate cancer.

Authors:  Rita Nader; Joelle El Amm; Jeanny B Aragon-Ching
Journal:  Asian J Androl       Date:  2018 May-Jun       Impact factor: 3.285
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.